Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials


Cangrelor is a new parenteral adenosine diphosphate P2Y12 receptor inhibitor with rapid, profound and reversible inhibition of platelet activity. The aim of this meta-analysis was to evaluate efficacy and safety of this new agent in patients undergoing percutaneous coronary intervention (PCI). We searched PubMed, Cochrane Library, EMBASE, Web of Science and… (More)
DOI: 10.1007/s11239-013-0998-5

7 Figures and Tables


  • Presentations referencing similar topics